The Domann Organization has built the Clinical Development & Operations team at Oncolytics Biotech

Chief Medical Officer
Executive Director, Clinical Operations
Executive Director Translational Sciences
Medical Director, Clinical Development
Thomas Heineman, M.D.
Amy Levin, BSN, RN
Richard Trauger, Ph.D.
Ruimei Li, M.D.

Oncolytics Biotech is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype – turning “cold” tumors “hot” – through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer.